Agile Therapeutics, Inc. (AGRX) is a ~$160 million market capitalization biotechnology company that has had quite a wild ride over the last years. AGRX is a women's healthcare company that focuses on the development and commercialization of prescription contraceptive products for women.
The key question for equity investors within the next month or so is whether the company's lead product, Twirla, will be approved by the FDA. This product has had a long regulatory history (see below) and it appears to finally be decision time.
I believe there is asymmetric risk/reward in AGRX equity shares